title: Panitumumab-induced interstitial lung disease in a case of metastatic colorectal cancer.
abstract: BACKGROUND
  A Japanese postmarketing survey of panitumumab revealed that panitumumab-associated interstitial lung disease (ILD) occurred in approximately 1% (19/1767) of patients, causing death in 36.8% of these cases.
  
  
  METHODS
  We report the case of a 60-year-old Japanese man who developed ILD associated with panitumumab therapy (third-line therapy) for metastatic sigmoid colon cancer involving the liver, lymph nodes, and lungs. 2 months after the initiation of panitumumab therapy, he developed a progressive nonproductive cough, dyspnea, and a fever, and was diagnosed with ILD. Intravenous pulse methylprednisolone treatment led to quick recovery. The patient had some risk factors for ILD associated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors.
  
  
  CONCLUSIONS
  Further studies are required to elucidate the association between anti-EGFR antibodies and ILD.
authors.affiliation: Division of Gastroenterology, Tsukuba University Hospital, Ibaraki, Japan.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Yamada
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Moriwaki
authors.forename: Kenji
authors.initials: K
authors.lastname: Matsuda
authors.forename: Yoshiyuki
authors.initials: Y
authors.lastname: Yamamoto
authors.forename: Akinori
authors.initials: A
authors.lastname: Sugaya
authors.forename: Daisuke
authors.initials: D
authors.lastname: Akutsu
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Murashita
authors.forename: Shinji
authors.initials: S
authors.lastname: Endo
authors.forename: Ichinosuke
authors.initials: I
authors.lastname: Hyodo
mesh_terms: D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D000077544:Panitumumab; D017211:Treatment Failure; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077544:Panitumumab